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Following a recent not peer-reviewed publication describing fatal toxicity of 
hydroxychloroquine in association with metformin in mice, the present study was undertaken 
to investigate this putative drug-drug interaction between hydroxychloroquine and metformin 
using pharmacovigilance data. 
Using Vigibase®, the WHO pharmacovigilance database, we found an increased risk 
of fatal outcomes with the association in comparison with each of the two drugs when used 
alone. 
This study suggests a pharmacovigilance signal of fatal outcome with the association 




















Introduction. Hydroxychloroquine was recently promoted in patients infected with COVID-
19 infection. A recent experimental study has suggested an increased toxicity of 
hydroxychloroquine in association with metformin in mice. 
Objective. The present study was undertaken to investigate reality of this putative drug-drug 
interaction between hydroxychloroquine and metformin using pharmacovigilance data. 
Methods. Using VigiBase®, the WHO pharmacovigilance database, we performed a 
disproportionality analysis (case/non-case study). Cases were reports of fatal outcomes with 
drugs of interest and non-cases all other reports for these drugs registered between the 1st 
January 2000 and the 31th December 2019. Data with hydroxychloroquine (or metformin) 
alone were compared with the association hydroxychloroquine + metformin. Results are 
reported as ROR (Reporting Odds Ratio) with their 95% confidence interval. 
Results. Of the 10,771 Individual Case Safety Reports (ICSR) involving 
hydroxychloroquine, 52 were recorded as “fatal outcomes”. In comparison with 
hydroxychloroquine alone, the association hydroxychloroquine + metformin was associated 
with a ROR value=57.7 (23.9-139.3). In comparison with metformin alone, the association 
hydroxychloroquine + metformin was associated with a ROR value=6.0 (2.6-13.8).  
Conclusion. Our study identified a signal for the association hydroxychloroquine + 
metformin that appears to be more at risk of fatal outcomes (particularly by completed 




Hydroxychloroquine is an antimalarial drug, today widely used in rheumatoid arthritis or 
lupus (1) that was recently proposed to treat COVID- 19 infections (2, 3), despite lack of 
clinical evidence (4). Besides efficacy, its clinical pharmacology (safety, drug-drug 
interactions) particularly in COVID-19 patients is not well known. In fact, a recent not peer-
reviewed publication (available in a preprint server) from American oncologists described 
fatal toxicity of hydroxychloroquine (or of chloroquine) in association with metformin in 
mice (5).  
2-Objective 
These aforementioned results led us to investigate reality of this putative drug-drug 
interaction in humans using a pharmacovigilance database. In fact, previous studies have 
shown that pharmacovigilance databases can be successfully used to detect drug-drug 
interactions (6). 
3-Methods 
The study was performed in Vigibase®, the WHO pharmacovigilance database, which 
registers all Individual Case Safety Reports (ICSRs) from more than 130 countries around the 
world. ICSRs are entered into VigiBase® after rigorous quality checks and deduplication (7).  
We extracted all ICSRs registered between the 1st January 2000 and the 31th 
December 2019 as “fatal outcomes” (HLGT-High Level Group Term in the SOC System 
Organ Class group “General Disorders and Administration Site Conditions” according to 
MedDRA®-Medical Dictionary for Regulatory Activities) in patients between 18 and 64 
years. In fact, we excluded ICSRs from patients with sex unknown as well as those < 18 years 
and > 64 years because in a preliminary analysis of Vigibase®, we failed to find any fatal 
outcome with the drug association (hydroxychloroquine + metformin) in patients < 18 and > 
64 years. As now usual to detect a pharmacovigilance signal in large pharmacovigilance 
databases (8), we performed a disproportionality analysis (case/non-case analysis) (8), with 
cases being occurrence of “fatal outcomes” with hydroxychloroquine (or chloroquine) 
(P01BA according to ATC classification of drugs) and non-cases all other ICSRs with 
hydroxychloroquine (or chloroquine) alone. Data with hydroxychloroquine (or chloroquine) 
alone were compared with the association hydroxychloroquine (or chloroquine) + metformin 
(A10BA). We also performed such analyses including other drugs used in diabetes, i.e. 
sulfonylureas (A10BB), alpha glucosidase inhibitors (A10BF), thiazolidinediones (A10BG), 
dipeptidyl peptidase 4 (DPP-4) inhibitors (A10BH), glucagon like peptide-1 (GLP-1) 
analogues (A10BJ) and sodium glucose cotransporter 2 (SGLT2) inhibitors (A10BK).  
Results are presented as Reporting Odds Ratio (ROR), a concept similar to OR in case 




Of the 21,580,375 deduplicated ICSRs recorded in VigiBase®, 7,961,942 met the inclusion 
criteria defined above with 10,771 involving hydroxychloroquine and 52 recorded as “fatal 
outcomes” with this drug. These 52 ICSRs were registered mainly in women (78.8%), main 
age group 45-64 years (55.8%). The majority came from United States of America (USA) 
(80.8%). Among these 52 ICSRs, 30 were described as “completed suicides”. With 
metformin, 1,413 deaths were found (including 1,083 suicides), 58.6% in men, mainly 
coming from USA (94.1%). The most frequent age group was 45-64 years (65.6%). Seven 
deaths were registered with the association hydroxychloroquine + metformin with 3 reports 
between 18-44 years and 4 between 45-64 years. Four were observed in men and 6 registered 
as completed suicides. All were from USA (table). 
For the total fatal reports, a ROR value = 57.7 (23.9-139.3) was associated to the 
association hydroxychloroquine + metformin in comparison to hydroxychloroquine alone. In 
comparison with metformin alone, the association hydroxychloroquine + metformin was 
associated with a ROR value = 6.0 (2.6-13.8). After excluding suicides, similar results were 
obtained for the association hydroxychloroquine + metformin versus hydroxychloroquine 
alone: ROR = 15.8 (2.1-120.6).  
None ICSR combining hydrochloroquine and other drugs used in diabetes 
(sulfonylureas, alpha glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1 
analogues, SGLT2 inhibitors) was found in VigiBase®.  
For chloroquine, 15 deaths were registered (60.0% in women, 73.3% between 18-44 
years, including 8 completed suicides. No fatal outcome was registered for the association 
chloroquine + metformin (or other drugs used in diabetes). 
5-Discussion 
The present study was performed to search a possible drug-drug interaction between 
hydroxychloroquine + metformin related to the recently developed off-label use of 
hydroxychloroquine in the field of COVID-19. In addition, some studies have investigated 
hydroxychloroquine in association with metformin in diabetic patients to achieve a better 
control of type-2 diabetes conditions (10). Conversely, metformin was studied as an 
adjunctive therapy for Systemic Lupus Erythematous, a condition for which 
hydroxychloroquine is routinely administered (11). In fact, our study was prompted by the 
paper from Rajeshkumar’s group (5) showing a higher mortality ratio (30-40%) in mice 
treated by the association in comparison with the control group receiving metformin alone. 
The authors found an increased number of autophagosomes in the heart, liver and kidneys of 
mice treated with the combination. They did not conclude about a univocal mechanism for 
their observation but suggested a synergistic effect between metformin, an inhibitor of the 
mitochondrial Complex I, and hydroxychloroquine that inhibits autophagy (5).  
Our study did not allow to discuss the possible mechanism of action but shows a clear 
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safety signal with the association hydroxychloroquine + metformin. We found that more 
reports of fatal outcomes (and especially suicides) are registered in VigiBase® with the 
association than with each one of the drug administered individually. No conclusion can be 
made for chloroquine due to the absence of lethal reports with the association.  
Of course, our work suffers from the classical biases of all pharmacovigilance studies: 
under- or selective reporting, lack of systematic information on doses and duration of 
exposure in Vigibase®. Of course, it is important to underline that ROR investigates the risk 
of ADR reporting rather than a true risk. Our study was not performed in COVID-19 patients 
but in those receiving hydroxychloroquine for rheumatic or dermatologic diseases. However, 
there is no reason to believe that the described drug-drug interaction could depend on the 
underlying disease(s). It was not possible to perform direct adjustments due to the 
characteristics of VigiBase®. However, Seabroke’s group found that in large 
pharmacovigilance databases, subgroup analyses (as performed in this study) improve both 
sensitivity and precision and are clearly beneficial over crude analyses (12,13).  
The fact that the completed suicide/non suicidal ratio is higher for the association than 
with the drugs alone could suggest an additional toxicity of hydroxychloroquine and 
metformin taken together. Since hydroxychloroquine doses are higher for COVID-19 than for 
lupus or rheumatoid arthritis, this might increase the significance of the signal. 
In contrast, the results of the present study have several important strengths. They are 
reflective of clinical conditions and cases were retrieved from the world’s largest 
pharmacovigilance database. It used a validated method to the first detections of a 
pharmacovigilance signals (7-9). We found high significant values of ROR suggesting a true 
association between the investigated factors. Our results extend the conclusions obtained in 
animals by Rajeshkumar et al (5) and should be considered as a meaningful 
pharmacovigilance signal of a drug-drug interaction between hydroxychloroquine and 
metformin. In fact, metformin is a widely used drug, particularly in aged and/or obese patients 




The present study found a pharmacovigilance signal that should be confirmed by other studies 
using other methods for drug-drug interaction detection. Our data suggest that the association 
increases the risk of death, and particularly death by completed suicide. From a clinical point 
of view, our results suggest a warning for metformin-treated diabetic patients receiving 
hydroxychloroquine, for example as self-medication or in off-label use for COVID-19. 
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Hydroxychloroquine 10,771 52 22 136% 0.20% 
Metformin 31,582 1,413 330 328% 0.10% 
Hydroxychloroquine 
+ metformin 
32 7 1 600% 3.12% 
Table: Number of total, fatal, non-suicidal reports and their ratios registered with 
hydroxychloroquine, metformin and their association in VigiBase®, the WHO 
pharmacovigilance database, between the 1st January 2000 and the 31th December 2019. 
 
 
